Compare Stocks › ABBV vs CME

AbbVie Inc. (ABBV) vs CME Group Inc. (CME): Which Is the Better Buy in 2026?

As of 2026-11-02, ABBV is overvalued at $295, with a DCF intrinsic value of $172 and a margin of safety of -71%. CME is overvalued at $303, with an intrinsic value of $240 and a margin of safety of -27%. Of the two, CME has the wider margin of safety.

ABBV
AbbVie Inc.
$294.89
VS
CME
CME Group Inc.
$303.14

Rewards

ABBV
  • ★AbbVie Inc. has maintained ROIC above 10% for 4 consecutive years, suggesting solid business economics.
  • ★Gross margin of 73.7% indicates strong pricing power — typical of businesses with significant intellectual property or brand strength.
  • ★AbbVie Inc. scores 82/100 on the Economic Moat Score (Wide Moat), with reinvestment efficiency as the strongest competitive dimension.
CME
  • ★Gross margin of 100.0% indicates strong pricing power — typical of businesses with significant intellectual property or brand strength.
  • ★CME Group Inc. scores 77/100 on the Economic Moat Score (Wide Moat), with margin stability as the strongest competitive dimension.
  • ★Free cash flow has grown at a 12.2% CAGR over the past 4 years, demonstrating strong earnings power growth.

Risks

ABBV
  • ⚠Buybacks have been poorly timed — 3 out of 4 years involved repurchases at relatively expensive valuations.
  • ⚠Insiders have sold $8.2M worth of stock in the past 3 months — significant insider liquidation.
  • ⚠Free cash flow has declined at a 9.8% CAGR over the past 4 years — a concerning trend.
CME
  • ⚠PEG ratio of 4.18 indicates the stock is expensive relative to its expected growth — the market may be pricing in more growth than analysts project.
  • ⚠Altman Z-Score of 0.53 places the company in the distress zone — financial patterns resemble those of companies that experienced bankruptcy.
  • ⚠Insiders have sold $5.7M worth of stock in the past 3 months — significant insider liquidation.

Key Valuation Metrics

Learn more →
ABBV
CME
Valuation
N/A
Free Cash Flow
$4.19B
N/A
FCF Yield
3.86%
50.67
Trailing P/E
24.85
18.24
Forward P/E
22.91
Quality & Moat
29.08%
ROIC
11.90%
N/A
ROE
16.13%
73.72%
Gross Margin
100.00%
0.60
PEG Ratio
4.18
Balance Sheet Safety
N/A
Net Debt / Equity
0.06
N/A
Interest Coverage
N/A
2.03
Net Debt / EBITDA
0.31
2.35%
Dividend Yield
1.72%
ABBV: 4Ties: 1CME: 3
ABBVCME

Historical Fundamentals

Learn more →
ABBV

Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

CME

Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

$1 Retained Earnings Test

Learn more →
ABBV
N/A
Net losses over 3 years — test not applicable
Company had negative cumulative retained earnings
Σ Retained
$-19.85B
Δ Market Cap
+$118.02B
Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
> $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer
CME
$526.78
created per $1 retained over 3 years
Exceptional Value Creator
Σ Retained
$71.5M
Δ Market Cap
+$37.66B
Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
> $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
> $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

Discounted Cash Flow (DCF) Analysis

Learn more →
ABBV
71.5% Overvalued
Price is 71.5% above estimated fair value
Current Price: $294.89
Fair Value: $172.00
Strongly undervalued
Undervalued
Fairly valued
Overvalued
Strongly overvalued
CME
26.5% Overvalued
Price is 26.5% above estimated fair value
Current Price: $303.14
Fair Value: $239.59
Strongly undervalued
Undervalued
Fairly valued
Overvalued
Strongly overvalued

Reverse DCF — Market-Implied Growth

Learn more →
ABBV

Requires positive FCF to compute implied growth rate.

CME

What growth rate is the market pricing in at $303?

+11.0%
Market-Implied Owner Earnings Growth
Standard FCF implies +11.4%

The market implies +11.0% Owner Earnings growth, roughly in line with history — reasonably priced.

Standard FCF implies +11.4%, reflecting ongoing growth investment.

Economic Moat Score

Learn more →
ABBV
82/100
Wide Moat
70+ Wide · 40-69 Narrow · <40 None

Wide moat with strength across all dimensions. Reinvestment Efficiency is the standout factor.

Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 4 years of fundamental data.
CME
77/100
Wide Moat
70+ Wide · 40-69 Narrow · <40 None

Wide moat driven primarily by margin stability. ROIC Consistency is the area most vulnerable to competitive pressure.

Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 4 years of fundamental data.

Forensic Accounting

Learn more →
ABBV
-2.86
Unlikely Manipulator
Above -1.78 = likely manipulator · -2.22 to -1.78 = grey zone

M-Score Trend

Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.
CME
-2.43
Unlikely Manipulator
Above -1.78 = likely manipulator · -2.22 to -1.78 = grey zone

M-Score Trend

Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

Ownership Breakdown

Learn more →
ABBV
Insiders 0.1%Institutions 77.4%Retail & Other 22.5%
No. of Institutional Holders5,303
High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.
CME
Insiders 0.4%Institutions 92.1%Retail & Other 7.5%
No. of Institutional Holders2,359
High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.

High insider ownership aligns management incentives with shareholders. Institutional concentration can indicate smart-money conviction but also crowding risk.

Insider Buying Activity

Learn more →
ABBV
0
Buys (3M)
0
Buys (12M)
No open market insider purchases found.
Open market purchases · includes direct & indirect ownership · excludes option exercises
CME
1
Buys (3M)
3
Buys (12M)
Total value (12M): $593,913
SHEPARD WILLIAM R
Director
$78,626
@ $269.27 · 2026-09-25
SHEPARD WILLIAM R
Director
$78,186
@ $230.64 · 2026-06-25
SHEPARD WILLIAM R
Director
$437,101
@ $297.55 · 2026-03-26
SHEPARD WILLIAM R
Director
$72,336
@ $270.92 · 2025-06-25
SHEPARD WILLIAM R
Director
$71,995
@ $262.76 · 2025-03-26
SHEPARD WILLIAM R
Director
$325,798
@ $227.99 · 2025-01-16
SHEPARD WILLIAM R
Director
$324,198
@ $227.99 · 2025-01-16
BENESH KATHRYN
Director
$3,595
@ $239.67 · 2024-12-27
Open market purchases · includes direct & indirect ownership · excludes option exercises

Open market purchases · includes direct & indirect ownership · excludes option exercises.

Insider Selling Activity

Learn more →
ABBV
1
Sells (3M)
4
Sells (12M)
Total value (12M): $18.92M
DONOGHOE NICHOLAS
Officer
$8.18M
@ $250.00 · 2026-08-14
PURDUE DAVID RYAN
Officer
$1.22M
@ $233.56 · 2026-03-04
SIATIS PERRY C.
General Counsel
$4.38M
@ $234.39 · 2026-03-02
SIATIS PERRY C.
General Counsel
$5.15M
@ $230.00 · 2026-02-25
SALEKI-GERHARDT AZITA
Chief Operating Officer
$8.41M
@ $198.42 · 2025-08-12
DONOGHOE NICHOLAS
Officer
$2.64M
@ $198.51 · 2025-08-05
STEWART JEFFREY RYAN
Officer
$12.36M
@ $210.08 · 2025-03-31
REENTS SCOTT T.
Chief Financial Officer
$3.75M
@ $212.34 · 2025-03-14
GONZALEZ RICHARD A
Director
$20.26M
@ $205.45 · 2025-03-03
RICHMOND TIMOTHY J
Officer
$4.47M
@ $210.45 · 2025-03-03
SIATIS PERRY C.
General Counsel
$5.82M
@ $208.69 · 2025-03-03
RICHMOND TIMOTHY J
Officer
$6.07M
@ $202.90 · 2025-02-26
BUCKBEE KEVIN K
Officer
$3.85M
@ $203.41 · 2025-02-26
SIATIS PERRY C.
General Counsel
$1.14M
@ $197.90 · 2025-02-20
BUCKBEE KEVIN K
Officer
$310,032
@ $172.24 · 2024-12-16
Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives
CME
3
Sells (3M)
13
Sells (12M)
Total value (12M): $30.27M
CUTINHO SUNIL KIRAN
Officer
$1.49M
@ $298.70 · 2026-10-27
GEPSMAN MARTIN J
Director
$121,000
@ $302.50 · 2026-10-22
DUFFY TERRENCE A
Chief Executive Officer
$4.12M
@ $274.44 · 2026-09-10
PIELL HILDA HARRIS
Officer
$1.75M
@ $304.63 · 2026-05-18
DUFFY TERRENCE A
Chief Executive Officer
$10.45M
@ $298.51 · 2026-05-15
MARCUS JONATHAN L
General Counsel
$1.10M
@ $333.37 · 2026-03-17
MARCUS JONATHAN L
Officer
$1.03M
@ $313.37 · 2026-03-17
VROMAN KENDAL L
Officer
$1.59M
@ $309.00 · 2026-03-12
DURKIN BRYAN T
Director
$1.30M
@ $309.65 · 2026-02-23
GEPSMAN MARTIN J
Director
$91,770
@ $305.90 · 2026-02-20
SUSKIND DENNIS A.
Director
$224,400
@ $300.00 · 2026-02-06
DUFFY TERRENCE A
Chief Executive Officer
$6.74M
@ $269.55 · 2025-12-11
FORD HAROLD EUGENE JR
Director
$263,530
@ $263.53 · 2025-11-03
MARCUS JONATHAN L
General Counsel
$102,704
@ $262.00 · 2025-09-18
MCCOURT TIMOTHY FRANCIS
Officer
$98,476
@ $259.83 · 2025-09-16
MARCUS JONATHAN L
General Counsel
$97,369
@ $258.96 · 2025-09-16
CUTINHO SUNIL KIRAN
Chief Technology Officer
$3.23M
@ $271.47 · 2025-08-26
KAYE DANIEL G
Director
$141,210
@ $282.42 · 2025-05-22
MARCUS JONATHAN L
General Counsel
$108,225
@ $277.50 · 2025-05-20
LOCKETT PHYLLIS M
Director
$294,553
@ $277.88 · 2025-05-19
GEPSMAN MARTIN J
Director
$81,951
@ $273.17 · 2025-05-15
SUSKIND DENNIS A.
Director
$271,280
@ $271.28 · 2025-04-29
GERDES LARRY G
Director
$1.06M
@ $265.11 · 2025-04-25
LUCAS DEBORAH J
Director
$385,425
@ $256.95 · 2025-03-14
DUFFY TERRENCE A
Chief Executive Officer
$7.78M
@ $259.18 · 2025-03-11
SPRAGUE SUZANNE
Chief Operating Officer
$385,249
@ $256.83 · 2025-03-03
PIELL HILDA HARRIS
Officer
$997,853
@ $250.47 · 2025-02-27
WINKLER JULIE
Officer
$2.89M
@ $249.17 · 2025-02-13
VROMAN KENDAL L
Officer
$1.27M
@ $250.00 · 2025-02-13
GEPSMAN MARTIN J
Director
$89,168
@ $222.92 · 2024-11-04
Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives

Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives.

🎭 Mr. Market's Mood

Learn more →
ABBV
FearGreed
😏Greed(72/100)

"Market is optimistic — be cautious and ensure you have a margin of safety"

Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.
CME
FearGreed
😏Greed(66/100)

"Market is optimistic — be cautious and ensure you have a margin of safety"

Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

Composite sentiment score based on market signals. Inspired by Buffett’s "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

⚖️ Buffett Signal

Learn more →
ABBV
⚪Awaiting DCF Data

The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

DCF Margin of Safety: N/AMr. Market's Mood: Greed (72)
CME
⚪Awaiting DCF Data

The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

DCF Margin of Safety: N/AMr. Market's Mood: Greed (66)
View ABBV Full AnalysisView CME Full Analysis

Frequently Asked Questions: ABBV vs CME

Is AbbVie Inc. or CME Group Inc. more undervalued in 2026?▼

Based on our discounted cash flow model, CME trades at a -26.5% margin of safety (intrinsic value $240 vs. price $303), compared to ABBV's -71.5% margin of safety (intrinsic $172 vs. $295).

Which stock has a wider economic moat, AbbVie Inc. or CME Group Inc.?▼

ABBV scores 82/100 (Wide moat), while CME scores 77/100 (Wide moat). The moat score measures competitive advantage durability across ROIC consistency, margin stability, revenue predictability, and reinvestment efficiency.

Is CME Group Inc. in financial distress?▼

CME's Altman Z-Score of 0.5 places it in the Distress zone, signaling elevated bankruptcy risk. ABBV scores 2.4 (Grey zone). The Altman Z-Score is a five-factor model that predicts insolvency within two years; scores below 1.81 indicate significant distress.

Which stock has higher return on invested capital, AbbVie Inc. or CME Group Inc.?▼

ABBV earns 29.1% ROIC versus CME's 11.9%. A higher ROIC means the company generates more profit per dollar of capital employed, a hallmark of durable competitive advantage in Buffett-style analysis.

Which dividend is safer, AbbVie Inc.'s or CME Group Inc.'s?▼

ABBV's dividend earns a safety score of 39/100 (Unsafe), compared to CME's 34/100 (Unsafe). ABBV has raised its dividend for 3 consecutive years.